Low-molecular-weight heparin improves survival in patients with cancer

Journal of Clinical Outcomes Management

Volumn 12, Issue 5, 2005, Pages 241-242

  Spigel, David R ^a  

^a SARAH CANNON RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; PLACEBO;

ADVANCED CANCER; BLEEDING; CANCER CHEMOTHERAPY; CANCER LOCALIZATION; CANCER SURVIVAL; CLINICAL TRIAL; DEATH; DRUG SAFETY; FOLLOW UP; HUMAN; LIFE EXPECTANCY; METASTASIS; PROSPECTIVE STUDY; QUESTIONNAIRE; RANDOMIZATION; SHORT SURVEY; SOLID TUMOR; VENOUS THROMBOEMBOLISM;

EID: 21244433969     PISSN: 10796533     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (2)

1. Lee AY, Levine MN, Baker RI, et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 2003;349:146-53.
2. Hettiarachchi RJ, Smorenburg SM, Ginsberg J, et al. Do heparins do more than just treat thrombosis? The influence of heparins on cancer spread. Thromb Haemost 1999;82:947-52.